1. Home
  2. FTRE

as of 12-29-2025 2:37pm EST

$17.29
$0.11
-0.63%
Stocks Health Care Medical Specialities Nasdaq

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Founded: 1996 Country:
United States
United States
Employees: N/A City: DURHAM
Market Cap: 1.5B IPO Year: N/A
Target Price: $12.64 AVG Volume (30 days): 1.4M
Analyst Decision: Hold Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -11.23 EPS Growth: N/A
52 Week Low/High: $3.97 - $20.26 Next Earning Date: 11-05-2025
Revenue: $2,759,900,000 Revenue Growth: 1.88%
Revenue Growth (this year): 3.17% Revenue Growth (next year): 0.11%

AI-Powered FTRE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 20 hours ago

AI Recommendation

hold
Model Accuracy: 74.51%
74.51%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Fortrea Holdings Inc. News

FTRE Breaking Stock News: Dive into FTRE Ticker-Specific Updates for Smart Investing

All FTRE News

Share on Social Networks: